Artis Ventures (AV)

Artis Ventures (AV) is a pioneering venture capital fund that specializes in the convergence of technology and biology, a field they have coined "TechBio." This innovative approach leverages advancements in AI, machine learning, and data science to transform healthcare and life sciences, aiming for scalable global impact. Notable investments include Rad AI, which uses artificial intelligence to enhance radiology, and Precision Neuroscience, a leader in neuroplasticity-promoting therapeutics. AV primarily focuses on data-driven life sciences companies that address critical healthcare challenges and are capable of achieving broad, scalable impact. Their industry scope spans oncology, cardiopulmonary, neurology, and beyond, often targeting companies with strong engineering and data science foundations. Geographically, AV invests globally, supporting founders from over 30 countries to foster innovations that can be scaled worldwide. The fund's strategy is centered around investing in early-stage startups with robust technical foundations and significant potential for positive health outcomes. They prefer to lead investment rounds and actively engage with their portfolio companies, offering not just capital but also strategic support and access to a vast network of industry experts. AV's investment team includes prominent figures like Laura Bordewieck Rippy and Luke Antal, who bring extensive experience and a strong track record in venture capital and entrepreneurial support. They are based in San Francisco, a hub for tech and biotech innovation. For startups looking to engage with AV, it's crucial to demonstrate a clear vision for scalable health solutions backed by solid technical expertise. AV values a data-driven approach and is keen on companies that can show potential for significant, measurable impact on global health outcomes.